Evidence mapPaperPMID 28487672Full record

ReviewFrontiers in endocrinology2017

The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Hélène Castel, Laurence Desrues, Jane-Eileen Joubert, Marie-Christine Tonon, Laurent Prézeau, Marie Chabbert, Fabrice Morin, Pierrick Gandolfo

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Targeting of G-protein coupled receptors in sepsis.Pharmacology & therapeutics · 2020
    Review
  11. Development of NovelBiomolecules · 2020
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Hélène CastelNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Laurence DesruesNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Jane-Eileen JoubertNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Marie-Christine TononNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Laurent PrézeauCNRS UMR 5203, INSERM U661, Institute of Functional Genomic (IGF), University of Montpellier 1 and 2, Montpellier, France.
Marie ChabbertUMR CNRS 6214, INSERM 1083, Faculté de Médecine 3, Angers, France.
Fabrice MorinNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Pierrick GandolfoNormandie University, UNIROUEN, INSERM, DC2N, Rouen, France.
Université de Rouen Normandie · FRCentre National de la Recherche Scientifique · FRDifférenciation et Communication Neuronale et Neuroendocrine · FRInserm · FRInstitut de Génomique Fonctionnelle · FRInstitute for Biomedicine · ITInstitute for Research and Innovation in Biomedicine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The urotensinergic system was previously considered as being linked to numerous physiopathological states, including atherosclerosis, heart failure, hypertension, pre-eclampsia, diabetes, renal disease, as well as brain vascular lesions. Thus, it turns out that the actions of the urotensin II (UII)/G protein-coupled receptor UT system in animal models are currently not predictive enough in regard to their effects in human clinical trials and that UII analogs, established to target UT, were not as beneficial as expected in pathological situations. Thus, many questions remain regarding the overall signaling profiles of UT leading to complex involvement in cardiovascular and inflammatory responses as well as cancer. We address the potential UT chemotactic structural and functional definition under an evolutionary angle, by the existence of a common conserved structural feature among chemokine receptorsopioïdergic receptors and UT, i.e., a specific proline position in the transmembrane domain-2 TM2 (P2.58) likely responsible for a kink helical structure that would play a key role in chemokine functions. Even if the last decade was devoted to the elucidation of the cardiovascular control by the urotensinergic system, we also attempt here to discuss the role of UII on inflammation and migration, likely providing a peptide chemokine status for UII. Indeed, our recent work established that activation of UT by a gradient concentration of UII recruits Gαi/o and Gα13 couplings in a spatiotemporal way, controlling key signaling events leading to chemotaxis. We think that this new vision of the urotensinergic system should help considering UT as a chemotactic therapeutic target in pathological situations involving cell chemoattraction.

Indexed as

chemokineG protein-coupled receptormigrationprolineurotensin IIUT

Identifiers

PMID28487672
PMCPMC5403833
OpenAlexW2607636539

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.